Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence: Overview01:16

Bioequivalence: Overview

1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

721
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
721
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

257
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
257
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

128
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
128
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Targeting the tumor microenvironment in genitourinary cancers: current progress and future directions in prostate cancer.

Expert opinion on biological therapy·2026
Same journal

Successful dose reduction of dupilumab in pediatric patients with atopic dermatitis in daily practice: results from the BioDay registry.

Expert opinion on biological therapy·2026
Same journal

Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma.

Expert opinion on biological therapy·2026
Same journal

Treating Castleman disease: insights into the use and efficacy of monoclonal antibodies.

Expert opinion on biological therapy·2026
Same journal

Targeting ineffective erythropoiesis in thalassemia: biologic therapies and emerging therapeutic strategies.

Expert opinion on biological therapy·2026
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026

Related Experiment Video

Updated: Jul 4, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Streamlining biosimilar development based on 20 years' experience.

Cecil Nick1

  • 1Parexel International, Uxbridge, Middlesex, England.

Expert Opinion on Biological Therapy
|February 5, 2024
PubMed
Summary
This summary is machine-generated.

Biosimilar development can be improved by tailoring clinical programs. A new biosimilarity report integrating various data is proposed to streamline regulatory approval and avoid unnecessary trials.

Keywords:
Clinical evidencebiosimilarcomparative efficacy trialsimilar biological medicinetailored developmenttotality of data

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.0K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

Related Experiment Videos

Last Updated: Jul 4, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.0K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

Area of Science:

  • Biopharmaceutical development
  • Regulatory science
  • Comparative efficacy studies

Background:

  • Biosimilar development requires optimized methodologies based on 20 years of accumulated knowledge.
  • A one-size-fits-all approach is inadequate due to the spectrum of biological medicine complexity.

Purpose of the Study:

  • To review the necessity of complex comparative efficacy trials in biosimilar development.
  • To propose a tailored approach for biosimilar regulatory approval.

Main Methods:

  • Review of key learnings in biosimilar development over the past two decades.
  • Analysis of the interrelationship between quality, potency, pharmacokinetics, pharmacology, immunogenicity, efficacy, and safety.
  • Examination of current and future regulatory thinking.

Main Results:

  • The complexity of biological medicines necessitates individualized development strategies.
  • Current regulatory frameworks may benefit from more flexible approaches.

Conclusions:

  • A tailored approach to biosimilar development is essential.
  • Introduction of a biosimilarity report is proposed to integrate evidence and guide clinical program design.
  • This aims to streamline marketing approval by focusing on the totality of evidence.